Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 181

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 181
---
 and diluted      (0.090)  (0.166)Weighted average number of common stocks outstanding, Basic and Diluted       17,818,483  15,875,455 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 12.

See accompanying notes to the consolidated financial statements.

 F-6Table of Contents

BIONEXUS GENE LAB CORP

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

  Common stock            Number     Additional  Accumulated  Accumulated other   Total   of    paid in  surplus/  comprehensive  stockholders’   shares  Amount  capital  (deficit)  losses  equity Balance as of December 31, 2022  14,476,513  $10,929,574  $(5,011,891 ) $1,156,392  $(409,062 ) $6,665,013                          Impacts arising from application of Topic 326  -   -   -   (371,627 )  -   (371,627 )                         Balance as of January 1, 2023 (restated)  14,476,513  $10,929,574  $(5,011,891 ) $784,765  $(409,062 ) $6,293,386                          Round up shares  1,044,351   1,046   -   -   -   1,046                          Issuance of shares*  1,437,500   5,750,000   -   -   -   5,750,000                          Issuance of shares#  709,299   510,695   -   -   -